Safety, efficacy and immunogenicity of concomitant molecular target drug or cytokine therapy and autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinoma

Safety, efficacy and immunogenicity of concomitant molecular target drug or cytokine therapy and autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinoma - Clinical study of combined molecular target drug or cytokine therapy and autologous tumor lysate-pulsed dendritic cell therapy for advanced renal cell carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014703

Enrollment

Registered

2014-07-29

Start date

2014-07-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma

Interventions

Tumor lysate-pulsed dendritic cells are injected on days 0, 14, 28, 42, 56 and 70. Molecular target drug or cytokine are administered in the proper dosage and usage.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Renal cell carcinoma patients who undergo surgical resection of primary lesion and receive molecular target drug or cytokine therapy for metastatic lesion: - Pathological diagnosis of renal cell carcinoma; - Tumor tissue is preserved after resection of primary lesion and tumor lysate is aseptically prepared; - Measurable lesion; - 20 years or more; - No serious abnormality in heart, lung, bone marrow, liver, and renal functions; - Written informed consent; - Outpatients.

Exclusion criteria

Exclusion criteria: Patients who have: - Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them; - Serious drug allergy; - Active infections; - Serious cardiac disease; - Active autoimmune diseases; - Continuous systemic administration of steroids within 4 weeks; - Other currently active malignancies; - Women during pregnancy, possible pregnancy, or breast-feeding; - Brain metastases;

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Immunological responses Antitumor effect Overall survival Progression-free survival	—

Countries

Japan

Contacts

Public ContactKazuhiro Kakimi

The University of Tokyo Hospital Department of Immunotherapeutics

immunotherapy-admin@umin.ac.jp03-5805-3161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026